Scinai Immunotherapeutics (SCNI) has released an update.
Scinai Immunotherapeutics has successfully met Nasdaq’s minimum bid price requirement, reviving its compliance and potentially bolstering investor confidence. The company has also initiated negotiations with the European Investment Bank to convert a significant loan into equity, aiming to satisfy Nasdaq’s shareholders’ equity condition. These strategic moves indicate Scinai’s proactive approach to maintaining its Nasdaq listing and its commitment to stakeholder value.
For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.
